Cargando…

Development and validation of 9-long Non-coding RNA signature to predicting survival in hepatocellular carcinoma

Primary hepatic carcinoma is 1 of the most common malignant tumors globally, of which hepatocellular carcinoma (HCC) accounts for 85% to 90%. Due to the high degree of deterioration and low early detection rate of HCC, most patients are diagnosed when they are already in the middle and advanced stag...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Benyuan, Yang, Min, Wang, Ming, Liu, Zhongwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249897/
https://www.ncbi.nlm.nih.gov/pubmed/32481346
http://dx.doi.org/10.1097/MD.0000000000020422
_version_ 1783538673184145408
author Deng, Benyuan
Yang, Min
Wang, Ming
Liu, Zhongwu
author_facet Deng, Benyuan
Yang, Min
Wang, Ming
Liu, Zhongwu
author_sort Deng, Benyuan
collection PubMed
description Primary hepatic carcinoma is 1 of the most common malignant tumors globally, of which hepatocellular carcinoma (HCC) accounts for 85% to 90%. Due to the high degree of deterioration and low early detection rate of HCC, most patients are diagnosed when they are already in the middle and advanced stages, and the prognosis are always poor. RNA sequencing data from the cancer genome atlas was used to explore differences in lncRNA expression profiles. LncRNA was extracted by gdcRNAtools in R package. Multivariate cox analysis was performed on the screened lncRNAs. The relationship between the lncRNA model and prognosis as well as clinical characteristics of patients with HCC was analyzed. Finally, a predictive nomogram in the the cancer genome atlas cohort was established and verified internally Based on the RNA sequencing survival analysis, a 9- lncRNAs prognosis model, including TMCC1-AS1, AC008892.1, AL031985.3, L34079.2, U95743.1, KDM4A-AS1, SACS-AS1, AC005534.1, LINC01116 was established. The 9-lncRNA prognosis model was a reliable tool for predicting prognosis of HCC, and the nomogram of this prognosis model could help clinicians to choose personalized treatment for HCC patients This model was significant to complement clinic characteristics of HCC and to promote personalized management of patients, it also provided a new idea for researches on the prognosis of HCC.
format Online
Article
Text
id pubmed-7249897
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-72498972020-06-15 Development and validation of 9-long Non-coding RNA signature to predicting survival in hepatocellular carcinoma Deng, Benyuan Yang, Min Wang, Ming Liu, Zhongwu Medicine (Baltimore) 5700 Primary hepatic carcinoma is 1 of the most common malignant tumors globally, of which hepatocellular carcinoma (HCC) accounts for 85% to 90%. Due to the high degree of deterioration and low early detection rate of HCC, most patients are diagnosed when they are already in the middle and advanced stages, and the prognosis are always poor. RNA sequencing data from the cancer genome atlas was used to explore differences in lncRNA expression profiles. LncRNA was extracted by gdcRNAtools in R package. Multivariate cox analysis was performed on the screened lncRNAs. The relationship between the lncRNA model and prognosis as well as clinical characteristics of patients with HCC was analyzed. Finally, a predictive nomogram in the the cancer genome atlas cohort was established and verified internally Based on the RNA sequencing survival analysis, a 9- lncRNAs prognosis model, including TMCC1-AS1, AC008892.1, AL031985.3, L34079.2, U95743.1, KDM4A-AS1, SACS-AS1, AC005534.1, LINC01116 was established. The 9-lncRNA prognosis model was a reliable tool for predicting prognosis of HCC, and the nomogram of this prognosis model could help clinicians to choose personalized treatment for HCC patients This model was significant to complement clinic characteristics of HCC and to promote personalized management of patients, it also provided a new idea for researches on the prognosis of HCC. Wolters Kluwer Health 2020-05-22 /pmc/articles/PMC7249897/ /pubmed/32481346 http://dx.doi.org/10.1097/MD.0000000000020422 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 5700
Deng, Benyuan
Yang, Min
Wang, Ming
Liu, Zhongwu
Development and validation of 9-long Non-coding RNA signature to predicting survival in hepatocellular carcinoma
title Development and validation of 9-long Non-coding RNA signature to predicting survival in hepatocellular carcinoma
title_full Development and validation of 9-long Non-coding RNA signature to predicting survival in hepatocellular carcinoma
title_fullStr Development and validation of 9-long Non-coding RNA signature to predicting survival in hepatocellular carcinoma
title_full_unstemmed Development and validation of 9-long Non-coding RNA signature to predicting survival in hepatocellular carcinoma
title_short Development and validation of 9-long Non-coding RNA signature to predicting survival in hepatocellular carcinoma
title_sort development and validation of 9-long non-coding rna signature to predicting survival in hepatocellular carcinoma
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249897/
https://www.ncbi.nlm.nih.gov/pubmed/32481346
http://dx.doi.org/10.1097/MD.0000000000020422
work_keys_str_mv AT dengbenyuan developmentandvalidationof9longnoncodingrnasignaturetopredictingsurvivalinhepatocellularcarcinoma
AT yangmin developmentandvalidationof9longnoncodingrnasignaturetopredictingsurvivalinhepatocellularcarcinoma
AT wangming developmentandvalidationof9longnoncodingrnasignaturetopredictingsurvivalinhepatocellularcarcinoma
AT liuzhongwu developmentandvalidationof9longnoncodingrnasignaturetopredictingsurvivalinhepatocellularcarcinoma